Alchemia pleased with cash position, Bionomics revenues up
19 August, 2005 by Helen SchullerBrisbane biopharma Alchemia's (ASX:ACL) financial results for the year ending June 3 reveal that the firm has $15.9 million in the bank to support the development program of its lead anti-cancer drug candidate ACL 16907.
New VC fund launched in New Zealand
19 August, 2005 by Ruth BeranIt has been a big year for regional biotech-flavoured venture funds to be launched from New Zealand. The latest is Finistere Partners, a San-Diego based venture capital firm, which has launched a new fund targeted at agricultural biotechnology and medical devices.
EpiPharm psoriasis treatment recommended for PBS reimbursement
19 August, 2005 by Ruth BeranExorex, a non-steroidal treatment for psoriasis exclusively marketed in Australia by Epitan's (ASX:EPT) wholly-owned subsidiary EpiPharm, has been recommended by the Pharmaceutical Benefits Advisory Committee for Pharmaceutical Benefits Scheme (PBS) reimbursement.
NeuroSolutions to collaborate with Epichem
19 August, 2005 by Helen SchullerNeuroSolutions, a subsidiary of newly listed neurology-focused biotech company NeuroDiscovery (ASX:NDL) has entered into a collaborative agreement with Epichem, a subsidiary of PharmAust (ASX:PAA) to assist with the development of one of NeuroSolutions' lead pain drug candidates, NSL-036.
Polartechnics lands distribution deal for US laser product
18 August, 2005 by Ruth BeranSydney-based Polartechnics (ASX:PLT) has signed an exclusive agreement with Reliant Technologies to distribute the California-based company's Fraxel laser product range in Australia, New Zealand and Oceania.
Ventracor growth sends annual loss up 68%
18 August, 2005 by Ruth BeranArtificial heart company Ventracor (ASX:VCR) has posted a net loss of $AUD26.6 million for 2004-05, up 68 per cent from $15.9 million in the previous financial year.
Antisense CEO takes good with bad in end-of-year figures
18 August, 2005 by Helen SchullerMelbourne's Antisense Therapeutics (ASX:ANP) has reported a full-year after-tax loss of AUD$6.2 million, up from $4.6 million from last year, in results described by CEO Mark Diamond as "good news tinged with less than positive news".
Stirling's ST810 shows beneficial effects in broiler chickens
16 August, 2005 by Ruth BeranStirling Products' (ASX:STI) second study into the effects of its lead beta agonist growth promotion product ST810 in broiler chickens has shown positive preliminary results, according to the company.
Mesoblast appoints executive chairman
16 August, 2005 by Helen SchullerAdult stem cell company Mesoblast (ASX:MSB) has appointed Michael Spooner as full-time executive chairman until June 30 next year.
CollTech raises $1.1m
16 August, 2005 by Helen SchullerWestern Australian collagen purification company CollTech (ASX:CAU) has raised AUD$1.1 million by way of a private placement to institutional and professional investors.
Cochlear chalks up record revenues
16 August, 2005 by Helen SchullerCochlear (ASX:COH), the world's top maker of hearing implants, has turned around a poor performance from last year to record a net profit of AUD$54.52 million, up 48 per cent from last year.
Stoush over, Polartechnics to hunt for profit
16 August, 2005 by Ruth BeranVictor Skladnev won't talk about last Friday's extraordinary general meeting of Polartechnics (ASX:PLT) shareholders. Referring only to the "disruptions" -- in which erstwhile chairman Richard Opara tried and failed to replace Skladnev as CEO -- Skladnev is keen to put the past behind him and focus on driving profits into the company.
Psivida and Solbec granted US patents
16 August, 2005 by Ruth BeranPsivida has been granted its fifth US patent for the classification of porous silicon into monodispersed particles with a tight size distribution.
Paragon Equity acquires 10% of BresaGen
16 August, 2005 by Ruth BeranAdelaide-based venture and development capital firm Paragon Equity has invested more than $AUD850,000 to acquire a 10 per equity holding of Adelaide biopharma BresaGen (ASX:BGN).
Amrad confirms Nash in CEO role
15 August, 2005 by Helen SchullerAndrew Nash has been named CEO of Amrad Corporation (ASX:AML), three months after he stepped into the role following the resignation of Peter Smith in May.
